The Upcoming Calithera Cystic Fibrosis Data Could Be Significant
Sundry Photography/iStock Editorial via Getty Images
Written By Dan Cohen.
Calithera (CALA) is guiding the market to expect a key data read-out in Q3 of this year from its ongoing CB-280 (arginase inhibitor) study in Cystic Fibrosis. The study intends…
